[Network Meta-analysis of randomized controlled trials of Chinese patent medicine for bradyarrhythmia].

• DOI: 10.19540/j.cnki.cjcmm.20190802.501
• Publication Date: 2020-03-01
• Authors: Hai-Yin Hu; Zhaochen Ji; Dandan Yu; Fengwen Yang; Hui Wang; Wenke Zheng; Junhua Zhang
• Keywords: Chinese patent medicine; Data extraction; Cochrane collaboration

To assess the clinical efficacy of Chinese patent medicine for bradyarrhythmia(BA) by using network Meta-analysis method. Relevant randomized controlled trials(RCTs) BA were retrieved from China National Knowledge Infrastructure(CNKI), WanFang Database, VIP database, SinoMed, PubMed and Cochrane Library. The retrieval time ranged commencement each database to February 2019. We completed literature screening data extraction according pre-determined inclusion exclusion criteria. quality studies was assessed bias risk assessment tool recommended Handbook Systematic Review 5.3. analyzed WinBUGS, STATA software used plotting. Finally, 46 RCTs included, involving 4 medicines 3 306 patients. According Meta-analysis, total effective rate in alleviating symptoms had 7 direct comparisons indirect comparisons. combined with routine therapy superior that therapy, statistically significant differences. order four as follows: Shenxian Shengmai Oral Liquid>Shensong Yangxin Capsules>Xinbao Pills>Ningxinbao Capsules. average heart Liquid Shensong Capsules results showed treatment BA. Due differences quantity included on different medicines, sequencing need be further verified.